Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2022-10-14 Regulatory Filings
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 21st October, 2022 at 06:30 P.M. to discuss the financial performance of the Company for the ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) announcing a scheduled conference call with investors and analysts to discuss the financial performance for the quarter and half year ended 30th September 2022. It includes dial-in details for the call but does not contain any financial data or results itself. The document is short (2397 characters) and serves as an announcement of the conference call event rather than the transcript or report of the call. Therefore, it fits the category of a Call Transcript announcement or notification. However, since it is only announcing the call and not the transcript, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement. The document is not the actual call transcript (CT) nor a financial report (IR).
2022-10-14 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) announcing a post quarterly financial result conference call scheduled for 21st October 2022 to discuss the financial performance for the quarter and half year ended 30th September 2022. It provides dial-in details for the conference call but does not contain any financial data or analysis itself. The document is short (2397 characters) and serves as an announcement of the conference call event rather than the financial report or transcript. Therefore, it fits best under the category of Call Transcript (CT) announcement, but since it is only announcing the call and not the transcript itself, the closest fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the conference call. Confidence is high due to clear context and content.
2022-10-14 English
General updates
M&A Activity Classification · 95% confidence The document is a short letter addressed to stock exchanges (BSE and NSE) providing an update on the completion of an acquisition transaction. It references a previous intimation and confirms that the acquisition of 100% stake in Curatio Health Care (I) Private Limited has been consummated. The document is brief (1252 characters) and serves as an announcement of a corporate event related to M&A activity. It does not contain detailed financial data, merger communications, or tender offer filings, but is clearly an update on a merger/acquisition transaction. Therefore, the most appropriate classification is M&A Activity (TAR).
2022-10-14 English
With reference to our earlier intimation dated 27-Sep-22 in relation to acquisition of 100% stake in Curatio Health Care (I) Private Limited, we hereby wish to inform that the transaction ....
Capital/Financing Update Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding the completion of an acquisition transaction. It references a previous intimation about acquiring 100% stake in Curatio Health Care (I) Private Limited and informs that the transaction has been consummated. The document is brief (1252 characters) and serves as an update on a financing or capital transaction rather than a full report or detailed announcement. It does not contain financial statements or detailed analysis, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it informs about a completed acquisition, which is a capital structure event.
2022-10-14 English
In compliance with the requirements under 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Compliance Certificate for ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) regarding submission of a Compliance Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It mentions the half year ended 30th September 2022, but does not contain any financial statements or detailed financial data. The document is short (1439 characters) and is a compliance certificate submission rather than a full financial report. This fits the criteria for a Regulatory Filing (RNS), as it is a regulatory compliance document and not a full interim or annual report.
2022-10-04 English
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2022 ,inter alia, to consider and approve We would like to inform ....
Regulatory Filings Classification · 95% confidence The document is a letter dated October 4, 2022, addressed to stock exchanges (BSE and NSE) informing them about the date of an upcoming Board Meeting scheduled for October 21, 2022. The purpose of the meeting is to consider and approve the audited financial results for the quarter and half year ended September 30, 2022. The document is an intimation or notice about the Board Meeting date and agenda, not the actual financial results or report. It is short (1722 characters) and serves as a notification under SEBI regulations. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain actual financial data or detailed report content.
2022-10-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.